Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

To investigate the therapeutic potential of targeting JAK/STAT in t(8;21) leukemia, we examined the effects of a JAK2-selective inhibitor TG101209 and a JAK1/2-selective inhibitor INCB18424 on t(8 ...

"The JAK2 mutation is not present in everyone with myelofibrosis, and there are other mutations as well." A second key ...

Importantly, the new study discovered that all major JAK2 mutation types—exon 12 (causing polycythemia vera), V617F (80% of all three types of MPN), and exon 16 (acute lymphoid leukemia ...

such as JAK2 exon 12 mutations • Sustained platelet count ≥ 450 × 10 9 /l • Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of ...